Signal Transduction and Targeted Therapy is an open access journal, which aims to accomplish timely publication of the latest discoveries and progress in both basic science and clinical research related to signal transduction and targeted therapy. It will include research on major human diseases, such as cancer, autoimmune disorders and others. Signal Transduction and Targeted Therapy is a multidisciplinary journal, covering topics including but not limited to molecular biology, cell biology, pharmacology, medicinal chemistry, computational chemistry, systems biology, bioinformatics, and clinical medicine. The impact factor of Signal Transduction and Targeted Therapy in 2019 is 13.493.
The Journal of Evidence-Based Medicine is the official English language journal of the Chinese Cochrane Centre. The journal aims to present the newest research results and promote the international understanding and development of evidence-based decision-making, research, practice, and education. Papers in any of the following fields will be considered: editorial, commentary, systematic review, clinical trial and register, methodology, policy-making and management, drug safety, education, patient safety, and knowledge translation. The journal encourages submissions from interdisciplinary studies and all manuscripts are blind peer reviewed.
Precision Clinical Medicine (PCM) is an open access academic journal that publishes on all aspects in the field of precision medicine. The journal aims to provide new theories, methods, and evidence for disease diagnosis, treatment, prevention，and prognosis, so as to establish a communication platform for clinicians and researchers that will impact practice of medicine.
Psychoradiology focuses on clinical and translational research of brain disorders by integrating radiology, psychology, psychiatry and neuroscience, with the aim to improve the diagnosis and prognosis of mental and behaviour problems.
Acta Epileptologica is the only english academic journal with CN number (CN51-1776/R) in China. It was first published in March 2018 and officially launched in July 2019. The printed version is issued quarterly.
